{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:04:47Z","timestamp":1791450287686,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["Peking University Health Science Center - University of Ulm Joint Center for Neuroscience fund (PKU2017ZC001-1)"],"award-info":[{"award-number":["Peking University Health Science Center - University of Ulm Joint Center for Neuroscience fund (PKU2017ZC001-1)"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00415-020-10236-4","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T12:03:31Z","timestamp":1601467411000},"page":"4537-4548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis"],"prefix":"10.1007","volume":"268","author":[{"given":"Qianshuo","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"10236_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","volume":"8","author":"P Peschl","year":"2017","unstructured":"Peschl P, Bradl M, Hoftberger R, Berger T, Reindl M (2017) Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol 8:529. https:\/\/doi.org\/10.3389\/fimmu.2017.00529","journal-title":"Front Immunol"},{"issue":"1","key":"10236_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","volume":"72","author":"TG Johns","year":"1999","unstructured":"Johns TG, Bernard CC (1999) The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72(1):1\u20139. https:\/\/doi.org\/10.1046\/j.1471-4159.1999.0720001.x","journal-title":"J Neurochem"},{"issue":"8","key":"10236_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","volume":"9","author":"M Reindl","year":"2013","unstructured":"Reindl M, Di Pauli F, Rostasy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9(8):455\u2013461. https:\/\/doi.org\/10.1038\/nrneurol.2013.118","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10236_CR4","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266(5):1280\u20131286. https:\/\/doi.org\/10.1007\/s00415-018-9122-2","journal-title":"J Neurol"},{"key":"10236_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, H\u00fcmmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B (2016) MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. https:\/\/doi.org\/10.1186\/s12974-016-0718-0","journal-title":"J Neuroinflamm"},{"issue":"21","key":"10236_CR6","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/wnl.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90(21):e1858\u2013e1869. https:\/\/doi.org\/10.1212\/wnl.0000000000005560","journal-title":"Neurology"},{"issue":"12","key":"10236_CR7","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","journal-title":"Brain"},{"issue":"2","key":"10236_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10236_CR9","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/wnl.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111\u2013e120. https:\/\/doi.org\/10.1212\/wnl.0000000000009758","journal-title":"Neurology"},{"key":"10236_CR10","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","volume":"44","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin B, Mathey G, Laplaud D, Thouvenot E, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett JL, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Jacob A (2020) Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Multiple Scler Relat Disord 44:102251. https:\/\/doi.org\/10.1016\/j.msard.2020.102251","journal-title":"Multiple Scler Relat Disord"},{"key":"10236_CR11","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.msard.2020.102376","volume":"44","author":"B Inan","year":"2020","unstructured":"Inan B, Gocmen R, Vural A, Colpak AI, Meinl E, Karabudak R, Tuncer A (2020) Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. Multiple Scler Relat Disord 44:102376. https:\/\/doi.org\/10.1016\/j.msard.2020.102376","journal-title":"Multiple Scler Relat Disord"},{"key":"10236_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fneur.2020.00089","volume":"11","author":"F Alshamrani","year":"2020","unstructured":"Alshamrani F, Alnajashi H, Shosha E, Casserly C, Morrow SA (2020) Case series: myelin oligodendrocyte glycoprotein-immunoglobulin g-related disease spectrum. Front Neurol 11:89. https:\/\/doi.org\/10.3389\/fneur.2020.00089","journal-title":"Front Neurol"},{"key":"10236_CR13","doi-asserted-by":"publisher","unstructured":"Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, Zhang W, Li J, Ren X, Fang F, Li W, Zhu Y, Peng B, Wang J, Zhong Y, Cui L (2020) Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study. Neurology(R) neuroimmunology & neuroinflammation 7 (3). https:\/\/doi.org\/10.1212\/nxi.0000000000000705","DOI":"10.1212\/nxi.0000000000000705"},{"key":"10236_CR14","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.msard.2020.102019","volume":"41","author":"J Rigal","year":"2020","unstructured":"Rigal J, Ciron J, L\u00e9pine Z, Biotti D (2020) Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Multiple Scler Relat Disord 41:102019. https:\/\/doi.org\/10.1016\/j.msard.2020.102019","journal-title":"Multiple Scler Relat Disord"},{"key":"10236_CR15","doi-asserted-by":"publisher","first-page":"116673","DOI":"10.1016\/j.jns.2020.116673","volume":"410","author":"JS Tzartos","year":"2020","unstructured":"Tzartos JS, Karagiorgou K, Tzanetakos D, Breza M, Evangelopoulos ME, Pelidou SH, Bakirtzis C, Nikolaidis I, Koutsis G, Notas K, Chroni E, Markakis I, Grigoriadis NC, Anagnostouli M, Orologas A, Parisis D, Karapanayiotides T, Papadimitriou D, Kostadima V, Elloul J, Xidakis I, Maris T, Zisimopoulou P, Tzartos S, Kilidireas C (2020) Deciphering anti-MOG IgG antibodies: clinical and radiological spectrum, and comparison of antibody detection assays. J Neurol Sci 410:116673. https:\/\/doi.org\/10.1016\/j.jns.2020.116673","journal-title":"J Neurol Sci"},{"key":"10236_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2020.1720676","author":"R Tao","year":"2020","unstructured":"Tao R, Qin C, Chen M, Yu HH, Wu LJ, Bu BT, Tian DS (2020) Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders. Int J Neurosci. https:\/\/doi.org\/10.1080\/00207454.2020.1720676","journal-title":"Int J Neurosci"},{"key":"10236_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577143","author":"R Pedapati","year":"2020","unstructured":"Pedapati R, Bhatia R, Singh N, Bali P, Gupta P, Saxena R, Dash D, Singh MB, Goyal V, Srivastava MVP (2020) Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum\u2014a north Indian tertiary care centre experience and review of literature. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577143","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10236_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.25648","volume":"87","author":"P Durozard","year":"2020","unstructured":"Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, Fritz S, Brunet C, Pelletier J, Marignier R, Audoin B (2020) Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 87(2):256\u2013266. https:\/\/doi.org\/10.1002\/ana.25648","journal-title":"Ann Neurol"},{"key":"10236_CR19","doi-asserted-by":"publisher","first-page":"101920","DOI":"10.1016\/j.msard.2019.101920","volume":"39","author":"I Lotan","year":"2019","unstructured":"Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I (2019) Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Multiple Scleros Relat Disord 39:101920. https:\/\/doi.org\/10.1016\/j.msard.2019.101920","journal-title":"Multiple Scleros Relat Disord"},{"issue":"1","key":"10236_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01658107.2019.1607883","volume":"44","author":"AS Lopez-Chiriboga","year":"2020","unstructured":"Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ (2020) Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic perineuritis. Neuro Ophthalmol 44(1):1\u20134. https:\/\/doi.org\/10.1080\/01658107.2019.1607883","journal-title":"Neuro Ophthalmol"},{"key":"10236_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09755-x","author":"J Loos","year":"2020","unstructured":"Loos J, Pfeuffer S, Pape K, Ruck T, Luessi F, Spreer A, Zipp F, Meuth SG, Bittner S (2020) MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-09755-x","journal-title":"J Neurol"},{"key":"10236_CR22","doi-asserted-by":"publisher","first-page":"4015075","DOI":"10.1155\/2019\/4015075","volume":"2019","author":"H Song","year":"2019","unstructured":"Song H, Zhou H, Yang M, Wang J, Liu H, Sun M, Xu Q, Wei S (2019) Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol 2019:4015075. https:\/\/doi.org\/10.1155\/2019\/4015075","journal-title":"J Ophthalmol"},{"key":"10236_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fneur.2019.01271","volume":"10","author":"Y Ren","year":"2019","unstructured":"Ren Y, Chen X, He Q, Wang R, Lu W (2019) Co-occurrence of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: a clinical phenomenon to be taken seriously. Front Neurol 10:1271. https:\/\/doi.org\/10.3389\/fneur.2019.01271","journal-title":"Front Neurol"},{"issue":"1","key":"10236_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/wno.0000000000000669","volume":"39","author":"I Jelcic","year":"2019","unstructured":"Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S (2019) Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. J Neuro Ophthalmol 39(1):3\u20137. https:\/\/doi.org\/10.1097\/wno.0000000000000669","journal-title":"J Neuro Ophthalmol"},{"key":"10236_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577002","author":"J Fujimori","year":"2019","unstructured":"Fujimori J, Takahashi T, Matsumoto Y, Fujihara K, Takai Y, Misu T, Nakashima I (2019) Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Beh\u00e7et\u2019s disease. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577002","journal-title":"J Neuroimmunol"},{"key":"10236_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","volume":"27","author":"M Etemadifar","year":"2019","unstructured":"Etemadifar M, Abbasi M, Salari M, Etemadifar F, Tavakoli H (2019) Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome. Multiple Scleros Relat Disord 27:127\u2013130. https:\/\/doi.org\/10.1016\/j.msard.2018.10.013","journal-title":"Multiple Scleros Relat Disord"},{"issue":"1","key":"10236_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sepulveda M, Rollot F, Armangue T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Sola-Valls N, Llufriu S, De Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflamm 16(1):134. https:\/\/doi.org\/10.1186\/s12974-019-1525-1","journal-title":"J Neuroinflamm"},{"key":"10236_CR28","doi-asserted-by":"publisher","first-page":"577078","DOI":"10.1016\/j.jneuroim.2019.577078","volume":"337","author":"P Brayo","year":"2019","unstructured":"Brayo P, Hartsell FL 3rd, Skeen M, Morgenlander J, Eckstein C, Shah S (2019) The clinical presentation and treatment of MOG antibody disease at a single academic center: a case series. J Neuroimmunol 337:577078. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577078","journal-title":"J Neuroimmunol"},{"key":"10236_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.msard.2019.05.006","volume":"33","author":"A Bellinvia","year":"2019","unstructured":"Bellinvia A, Pasto L, Razzolini L, Fratangelo R, Prestipino E, Fonderico M, Tudisco L, Amato MP (2019) The clinical spectrum of anti-MOG associated acquired demyelinating disorders: three case-reports. Multiple Scleros Relat Disord 33:51\u201354. https:\/\/doi.org\/10.1016\/j.msard.2019.05.006","journal-title":"Multiple Scleros Relat Disord"},{"key":"10236_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.msard.2019.01.035","volume":"29","author":"T Kamada","year":"2019","unstructured":"Kamada T, Miura S, Harada M, Irie A, Kikuchi S, Taniwaki T, Kurata S, Uchiyama Y, Takahashi T (2019) Bilateral cingulate cortices lesions in two autoantibodies directed against MOG (MOG-Ab)-positive patients. Multiple Scleros Relat Disord 29:108\u2013110. https:\/\/doi.org\/10.1016\/j.msard.2019.01.035","journal-title":"Multiple Scleros Relat Disord"},{"issue":"12","key":"10236_CR31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1177\/1352458518765677","volume":"24","author":"D Biotti","year":"2018","unstructured":"Biotti D, Lerebours F, Bonneville F, Ciron J, Clanet M, Brassat D (2018) Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder. Multiple Scleros (Houndmills, Basingstoke, England) 24(12):1645\u20131647. https:\/\/doi.org\/10.1177\/1352458518765677","journal-title":"Multiple Scleros (Houndmills, Basingstoke, England)"},{"key":"10236_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jns.2018.01.042","volume":"387","author":"JM Gutman","year":"2018","unstructured":"Gutman JM, Kupersmith M, Galetta S, Kister I (2018) Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures. J Neurol Sci 387:170\u2013173. https:\/\/doi.org\/10.1016\/j.jns.2018.01.042","journal-title":"J Neurol Sci"},{"issue":"1","key":"10236_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","volume":"75","author":"SHM Hamid","year":"2018","unstructured":"Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhojak M, Woodhall M, Waters P, Appleton R, Duddy M, Jacob A (2018) Seizures and encephalitis in myelin oligodendrocyte glycoprotein igg disease vs aquaporin 4 IgG disease. JAMA Neurol 75(1):65\u201371. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3196","journal-title":"JAMA Neurol"},{"issue":"11","key":"10236_CR34","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS Lopez-Chiriboga","year":"2018","unstructured":"Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-Associated disorders. JAMA Neurol 75(11):1355\u20131363. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1814","journal-title":"JAMA Neurol"},{"issue":"2","key":"10236_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC, Andrews P, Barton J, Burrow J, Butzkueven H, Cairns A, Calvert S, Caruana P, Chelakkadan S, Clark D, Fraser C, Freeman J, Gill D, Grattan-Smith P, Gupta S, Hardy T, Kothur K, Ling S, Lopez J, Malone S, Marriott M, Nosadini M, O\u2019Grady G, Orr C, Ouvrier R, Parratt J, Patrick E, Pilli D, Riminton D, Riney K, Rodriguez-Casero V, Ryan M, Scheffer I, Shah U, Shuey N, Spooner C, Subramanian G, Tea F, Thomas T, Thompson J, Troedson C, Ware T, Webster R, Yiannikas C, Yiu E, Zou A (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89(2):127\u2013137. https:\/\/doi.org\/10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10236_CR36","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/nxi.0000000000000322","volume":"4","author":"R Ogawa","year":"2017","unstructured":"Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4(2):e322. https:\/\/doi.org\/10.1212\/nxi.0000000000000322","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10236_CR37","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R (2017) Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Scleros (Houndmills, Basingstoke, England) 23(10):1377\u20131384. https:\/\/doi.org\/10.1177\/1352458516678474","journal-title":"Multiple Scleros (Houndmills, Basingstoke, England)"},{"key":"10236_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","volume":"381","author":"M Bouzar","year":"2017","unstructured":"Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, Reindl M, Jarius S (2017) Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients. J Neurol Sci 381:240\u2013244. https:\/\/doi.org\/10.1016\/j.jns.2017.08.3254","journal-title":"J Neurol Sci"},{"issue":"7","key":"10236_CR39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/1352458515614093","volume":"22","author":"S Siritho","year":"2016","unstructured":"Siritho S, Sato DK, Kaneko K, Fujihara K, Prayoonwiwat N (2016) The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Multiple Scleros (Houndmills, Basingstoke, England) 22(7):964\u2013968. https:\/\/doi.org\/10.1177\/1352458515614093","journal-title":"Multiple Scleros (Houndmills, Basingstoke, England)"},{"issue":"12","key":"10236_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273\u20131277. https:\/\/doi.org\/10.1212\/WNL.0b013e31826aac4e","journal-title":"Neurology"},{"issue":"6","key":"10236_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1212\/nxi.0000000000000625","volume":"6","author":"S Winklmeier","year":"2019","unstructured":"Winklmeier S, Schl\u00fcter M, Spadaro M, Thaler FS, Vural A, Gerhards R, Macrini C, Mader S, Kurne A, Inan B, Karabudak R, \u00d6zbay FG, Esendagli G, Hohlfeld R, K\u00fcmpfel T, Meinl E (2019) Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm 6(6):625. https:\/\/doi.org\/10.1212\/nxi.0000000000000625","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10236_CR42","doi-asserted-by":"publisher","first-page":"175628641876169","DOI":"10.1177\/1756286418761697","volume":"11","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stuve O (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697. https:\/\/doi.org\/10.1177\/1756286418761697","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10236_CR43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostasy K, Neuteboom R, Deiva K, Lim M (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75(4):478\u2013487. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4601","journal-title":"JAMA Neurol"},{"issue":"5","key":"10236_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19(5):391\u2013401. https:\/\/doi.org\/10.1016\/s1474-4422(20)30070-3","journal-title":"Lancet Neurol"},{"issue":"8","key":"10236_CR45","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","volume":"67","author":"J Palace","year":"2010","unstructured":"Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67(8):1016\u20131017. https:\/\/doi.org\/10.1001\/archneurol.2010.188","journal-title":"Arch Neurol"},{"issue":"3","key":"10236_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","volume":"19","author":"M Jury\u0144czyk","year":"2019","unstructured":"Jury\u0144czyk M, Jacob A, Fujihara K, Palace J (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol 19(3):187\u2013195. https:\/\/doi.org\/10.1136\/practneurol-2017-001787","journal-title":"Pract Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10236-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:45:19Z","timestamp":1659055519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10236-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10236"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10236-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All of the authors declare no financial or other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}